MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, announced today the presentation of results of a successful randomized, double-blind, multi-center, pivotal phase 3 trial of Aquavan® (fospropofol disodium) Injection in patients undergoing flexible bronchoscopy. Primary and secondary efficacy endpoint results, as well as safety data, were presented at CHEST 2007, the annual conference of the American College of Chest Physicians, in Chicago. Aquavan is an investigational drug that is being studied as a sedative-hypnotic agent in patients undergoing brief surgical or diagnostic procedures.
